Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumor Spine Metastases 1Sarcoma 1Rectal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Lymphoma, Follicular 1Locally Advanced Colon Cancer 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1Anxiety Disorders 1Amenorrhea 1

Interventions

Iodine-131 21lenvatinib 17Magnetic Resonance Spectroscopy 17trametinib 13Sorafenib 13Thyrotropin Alfa 12pembrolizumab 11dabrafenib 11Thyroidectomy 10Surgical Procedures, Operative 10Thyroxine 9Paclitaxel 9vandetanib 8selpercatinib 8Sunitinib 7Nivolumab 7Fluorodeoxyglucose F18 7cabozantinib 6anlotinib 6Everolimus 6Biopsy 6pazopanib 5Vemurafenib 5Triiodothyronine 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Iodine-124 5Cyclophosphamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Postoperative Period × Clear all
NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
24 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡